Results of NovaRx's Lucanix Phase III trial in non-small cell lung cancer to be presented at ESMO 2013

Published on September 26, 2013 at 2:51 AM · No Comments

NovaRx Announces Results of Lucanix® Phase III Therapeutic Vaccine Trial for Post-frontline Maintenance Therapy in Non-small Cell Lung Cancer to Be Presented at ESMO.

NovaRx Corporation announced that the detailed results from the randomized Phase III trial of Lucanix® (belagenpumatucel-L) post-frontline maintenance therapy in non-small cell lung cancer will be presented at the European Society for Medical Oncology 2013 annual meeting in Amsterdam. The results will be presented in "Presidential Session I: Best and Late Breaking Abstracts" on 28 September 2013, which starts at 1:45 pm. 

The primary endpoint of improving overall survival in 532 patients was not met primarily due to the inclusion of patients more than 12 weeks following the completion of frontline chemotherapy.  In this predefined subgroup of 305 stage IIIB/IV patients, a median survival of 20.7 months was observed for Lucanix compared to 13.4 months for the control (HR 0.75).  In a the predefined subgroup of these patients with a histology of squamous cell carcinoma a media survival of 20.7 months was observed for Lucanix compared to 12.3 months for the control (HR 0.58).  In the predefined subgroup of these patients who received radiation therapy prior to enrollment a media survival of 40.1 months was observed for Lucanix compared to 10.3 months for the control (HR 0.45).

Source:

NovaRx Corporation

Read in | English | Español | Français | Deutsch | Português | Italiano | 日本語 | 한국어 | 简体中文 | 繁體中文 | Nederlands | Русский | Svenska | Polski
Comments
The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News-Medical.Net.
Post a new comment
Post
You might also like... ×
Robot-assisted surgery to control prostate cancer effective in controlling disease for 10 years